| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 10.0 |
| Net income | -30.9 | -12.5 |
| EPS (diluted, $ a share) | $-0.85 | $-8.07 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NYSE: EVMN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Evommune, Inc.: key numbers
- Share price
- $7.10Close, Nov 16
- Market cap
- $294M
- Shares outstanding
- 41.35MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Evommune, Inc.
All →Evommune Financial Results
Evommune, Inc. reported financial results for the third quarter ended September 30, 2026, and provided a business update on its immunology pipeline. The company highlighted the in-licensing of EVO570, positive Phase 2a data for EVO301 in atopic dermatitis, and confirmed a cash runway extending into the second half of 2029.
“We have built a portfolio of differentiated immunology assets spanning biologics and small molecules, each aimed at a distinct upstream driver of chronic inflammation. The in-licensing of EVO570 expands our reach into T- and B-cell-driven autoimmune diseases, while the EADV data strengthen our conviction that EVO301 has the potential to become a foundational therapy in atopic dermatitis, if approved.”
Luis Peña, President and Chief Executive Officer
“As we advance EVO301 into Phase 2b and expand into ulcerative colitis, 2027 will be a year of execution and clinical catalysts for Evommune, with additional new clinical studies across EVO646 and EVO570 and Phase 2b migraine top-line data expected from EVO756. With a strong balance sheet and an experienced team, we believe we are well positioned to deliver on these milestones and create meaningful value for patients and stockholders.”
Luis Peña, President and Chief Executive Officer
Evommune Licensing Deal with Hinova Pharmaceuticals Inc.
Evommune announced it has entered into an exclusive license agreement with Hinova Pharmaceuticals for EVO570, an oral VAV1-directed molecular glue degrader. Evommune acquired worldwide rights (excluding Greater China) to develop, manufacture, and commercialize the candidate, which it plans to develop for rheumatoid arthritis.
- Counterparty
- Hinova Pharmaceuticals Inc.
Evommune Licensing Deal with Hinova Pharmaceuticals Inc. Worth $30M
Evommune has entered into an exclusive license agreement with Hinova Pharmaceuticals to develop and commercialize EVO570, a VAV1 molecular glue degrader, globally excluding Greater China. Evommune will pay $20 million upfront in cash and $10 million in pre-funded warrants, with Hinova eligible for up to $1.07 billion in additional milestone payments plus tiered royalties.
- Value
- $30M
- Counterparty
- Hinova Pharmaceuticals Inc.
- Term
- Royalty Term
Evommune Clinical Trial Data
Evommune presented Phase 2a proof-of-concept data for EVO301 in patients with moderate-to-severe atopic dermatitis, showing a 55% mean reduction in EASI scores at Week 12 compared to 22% for placebo. The trial validated IL-18 inhibition as a novel therapeutic approach with a favorable safety profile, and the company plans to initiate a Phase 2b dose-ranging trial in mid-2027.
- Counterparty
- European Academy of Dermatology and Venereology (EADV)
Evommune Clinical Trial Data
Evommune announced that Phase 2a proof-of-concept data for EVO301, its IL-18 binding protein candidate for moderate-to-severe atopic dermatitis, will be presented in a late-breaking oral session at the EADV 2026 Congress. The presentation will build on topline results reported earlier in the year as the company prepares to initiate a Phase 2b dose-ranging study in mid-2027.
- Counterparty
- European Academy of Dermatology & Venereology (EADV)
Evommune Investor Presentation
Evommune, Inc. has filed an updated corporate presentation as an exhibit to its 8-K, providing a strategic overview of its clinical-stage portfolio including EVO756, EVO301, and EVO646. The presentation outlines the company's focus on chronic inflammatory diseases and highlights its leadership team's track record of approximately 30 approved NDAs and BLAs.